Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Presidential Symposium 2

3323 - CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC


09 Oct 2016


Presidential Symposium 2


Mark Socinski


Annals of Oncology (2016) 27 (6): 1-36. 10.1093/annonc/mdw435


M. Socinski1, B. Creelan2, L. Horn3, M. Reck4, L. Paz-Ares5, M. Steins6, E. Felip7, M. van den Heuvel8, T.E. Ciuleanu9, F. Badin10, N. Ready11, J.N. Hiltermann12, S. Nair13, R. Juergens14, S. Peters15, E. Minenza16, W.J. Geese17, P. Bhagavatheeswaran18, A. Chen19, D.P. Carbone20

Author affiliations

  • 1 Medical Oncology, UPMC Cancer Center, 15232 - Pittsburgh/US
  • 2 Thoracic Oncology, H. Lee Moffitt Cancer Center, Tampa/US
  • 3 Department Of Medicine, Vanderbilt University Medical Center, 37212 - Nashville/US
  • 4 Thoracic Oncology, LungenClinic Grosshansdorf, Airway Research Center North (ARCN), 22927 - Grosshansdorf/DE
  • 5 Medical Oncology, Hospital Universitario Doce de Octubre & CNIO, 28041 - Madrid/ES
  • 6 Oncology, Thoraxklinik-Heidelberg gGmbH, Heidelberg/DE
  • 7 Oncologia Médica, Hospital Universitari Vall d’Hebron, 08035 - Barcelona/ES
  • 8 Thoracic Oncology, Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam/NL
  • 9 Medical Oncology, Prof. Dr. Ion Chiricuta Institute of Oncology and UMF Iuliu Hatieganu, Cluj-Napoca/RO
  • 10 Oncology, Baptist Health Lexington, Lexington/US
  • 11 Oncology, Duke University Medical Center, 27710 - Durham/US
  • 12 Pulmology Oncology, University of Groningen and University Medical Center Groningen, 9700 RB - Groningen/NL
  • 13 Hematology-medical Oncology, Lehigh Valley Health Network, Allentown/US
  • 14 Oncology, Juravinski Cancer Centre, Ontario/CA
  • 15 Oncology, University of Lausanne, Lausanne/CH
  • 16 Oncology, Ospedale S. Maria Nuova, Terni/IT
  • 17 Oncology, Bristol-Myers Squibb, 08648 - Princeton/US
  • 18 Global Biometric Sciences, Bristol-Myers Squibb, 08648 - Princeton/US
  • 19 Global Clinical Research Oncology, Bristol-Myers Squibb, Princeton/US
  • 20 Department Of Medical Oncology, Ohio State University Comprehensive Cancer Center, 43210 - Columbus/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3323


Nivolumab improves OS compared with docetaxel in previously treated NSCLC. In a phase 1 study (CheckMate 012), nivolumab showed promising activity and manageable safety as monotherapy and in combination with ipilimumab in treatment naive advanced NSCLC. CheckMate 026 (NCT02041533), an open-label, randomized phase 3 study, evaluated the efficacy of nivolumab vs IC PT-DC as first-line therapy in stage IV/recurrent PD-L1–positive NSCLC.


Patients with histologically confirmed and previously untreated stage IV or recurrent NSCLC, ECOG PS 0–1, and PD-L1 positivity were randomized 1:1 to receive nivolumab 3 mg/kg IV Q2W or IC PT-DC (histology-based) Q3W (up to 6 cycles) until disease progression or unacceptable toxicity. Patients with EGFR/ALK mutations sensitive to targeted therapy were excluded. Patients on IC PT-DC could crossover to nivolumab upon progression. The primary objective was comparison of PFS (per RECIST 1.1) as assessed by an independent radiology review committee in patients with ≥5% PD–L1 tumor expression at randomization.


A total of 541 patients were randomized to treatment. In patients with ≥5% PD-L1 expression (n = 423), nivolumab did not improve PFS (HR, 1.15; 95% CI 0.91 to 1.45; P = 0.25). Median PFS was 4.2 mo and 5.9 mo with nivolumab and IC PT-DC, respectively. Among all treated patients, any grade and grade 3/4 treatment-related adverse events were 71% and 18% with nivolumab, as compared to 92% and 51% with IC PT-DC, respectively. Secondary endpoints including PFS in all randomized patients, OS, and ORR will be presented.


Nivolumab did not show superior PFS compared to IC PT-DC as first-line therapy in stage IV/recurrent NSCLC patients with ≥5% PD-L1 tumor expression. The safety profile of nivolumab was favorable to IC PT-DC and consistent with previous studies. Nivolumab plus ipilimumab and nivolumab plus chemotherapy are being evaluated in a phase 3 trial in previously untreated NSCLC (CheckMate 227).

Clinical trial identification


Legal entity responsible for the study

Bristol-Myers Squibb


Bristol-Myers Squibb


B. Creelan: Honoraria and research funding from Boehringer-Ingelheim. Received Speakers' Bureau payment and Travel, Accommodations, and Expenses from Bristol-Myers Squibb and AstraZeneca L. Horn: Consulting/Advisory Role with Genetech and Merck (compensated) & BMS, BI, Xcovery and Bayer (compensated). Research funding from AstraZeneca. Relationship with Biodesix. M. Reck: Consulting and Speakers' Bureau: Roche, Eli Lilly, Bristol Myers Squibb, MSD, AstraZeneca, Pfizer, Boehringer-Ingelheim, Celgene. M. Steins: The author reports Honoraria and Consulting or Advisory Role for BMS. E. Felip: The author reports honoraria and consulting/advisory role with Boeheringer Ingelheim, MSD, Eli Lilly, Roche, Pfizer, Novartis, BMS, Celgene. The author reports Speakers Bureau for BMS, Novartis, Roche. T.E. Ciuleanu: The author reports advisory board work for Amgen, Astellas, AZ, BMS, Janssen, Lilly, Merck, Merck Sharp and Dohme. N. Ready: The author reports honoraria from BMS, Celgene, Heat Biologics and travel/accommodations/expenses from AZ. S. Nair: Received Research Funding from Bristol-Myers Squibb, Celldex—site PI for trials. R. Juergens: The author reports: Research Funding from AZ/MedImmune, BMS, Merck Sharp & Dohme, Novartis; Honoraria from Bayer, BMS, BI, BetaPharma, AZ, AZ/MedImmune, Roche Canada; Consulting /Advisory role for AZ, BI, BMS, Lilly, Novartis, Pfizer and Merck Sharp&Dohme. S. Peters: The author reports a consulting or advisory role with Roche, MSD, Lilly, Merck, Serono, Pfizer, AZ, Amgen, Celgene, BI, BMS. W.J. Geese: The author reports employment from BMS, stock or other ownership from BMS, and travel/accommodations/expenses from BMS. P. Bhagavatheeswaran, A. Chen: The author reports Employment and Stock or Other Ownership from BMS. D.P. Carbone: Writing Assistance provided by StemScientific, consulting for Genentech, Bristol Myers Squibb, Boehringer Ingelheim, Novartis, Pfizer, and Clovis (in the past but within the last 36 months). Grants from Bristol-Myers Squibb. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings